.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Colorcon
Daiichi Sankyo
McKesson
Express Scripts
Queensland Health
Mallinckrodt
Healthtrust
Fuji

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,372,780

« Back to Dashboard

Summary for Patent: 6,372,780

Title: Methods of treating cell lines expressing multidrug resistance P-glycoprotein
Abstract:Now taxoids of general formula (I) ##STR1## their preparation and pharmaceutical compositions containing them. The new products of general formula (I) in which Z represents a radical of general formula (II): ##STR2## display noteworthy antitumor and antileukaemic properties.
Inventor(s): Bouchard; Herve (Ivry-sur-Seine, FR), Bourzat; Jean-Dominique (Vincennes, FR), Commer.cedilla.on; Alain (Vitry-sur-Seine, FR)
Assignee: Aventis Pharma S.A. (Antony Cedex, FR)
Application Number:09/752,779
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,372,780

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France95 03545Mar 27, 1995
France95 15381Dec 22, 1995

International Patent Family for Patent: 6,372,780

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary9801204► Subscribe
Hungary223666► Subscribe
Hungary9801201► Subscribe
Greece3032316► Subscribe
Greece3031526► Subscribe
Georgia, Republic ofP20002211► Subscribe
Georgia, Republic ofP20002188► Subscribe
France2742754► Subscribe
France2732340► Subscribe
Finland953645► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Mallinckrodt
Healthtrust
QuintilesIMS
Merck
Baxter
Deloitte
Chinese Patent Office
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot